Mark Guinan
Director/Board Member bij UPHEALTH, INC.
Vermogen: 13 M $ op 29-02-2024
Profiel
Momenteel bekleedt Mark J. Guinan de functie van Chief Financial Officer & Executive Vice President bij Quest Diagnostics, Inc. De heer Guinan is tevens lid van de raad van bestuur van Myovant Sciences Ltd., Q Squared Solutions Holdings Ltd. en Roivant Sciences, Inc. Daarvoor was hij Chief Financial Officer & Senior Vice President bij Hill-Rom Holdings, Inc., Vice President-Finance van de Global Pharmaceutical Group, Chief Procurement Officer bij Johnson & Johnson en Principal bij Procter & Gamble Co. Mark J. Guinan behaalde een bachelorgraad aan de Universiteit van Notre Dame en een MBA aan de Olin Business School.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
08-03-2023 | 106 038 ( 0.10% ) | 13 M $ | 29-02-2024 | |
UPHEALTH INC
0.86% | 31-01-2024 | 160 606 ( 0.86% ) | 62 636 $ | 29-02-2024 |
Actieve functies van Mark Guinan
Bedrijven | Functie | Begin |
---|---|---|
UPHEALTH, INC. | Director/Board Member | 05-12-2022 |
Q Squared Solutions Holdings Ltd.
Q Squared Solutions Holdings Ltd. Medical/Nursing ServicesHealth Services Part of IQVIA Holdings, Inc., Q Squared Solutions Holdings Ltd. is a British company that provides health services. The private company is based in Reading, UK. | Director/Board Member | - |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Director/Board Member | - |
Eerdere bekende functies van Mark Guinan
Bedrijven | Functie | Einde |
---|---|---|
MYOVANT SCIENCES LTD. | Director/Board Member | 10-03-2023 |
QUEST DIAGNOSTICS INCORPORATED | Director of Finance/CFO | 11-07-2022 |
HILL-ROM HOLDINGS, INC. | Director of Finance/CFO | 19-07-2013 |
JOHNSON & JOHNSON | Corporate Officer/Principal | 01-01-2010 |
PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Opleiding van Mark Guinan
University of Notre Dame | Undergraduate Degree |
Olin Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
JOHNSON & JOHNSON | Health Technology |
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
QUEST DIAGNOSTICS INCORPORATED | Health Services |
UPHEALTH, INC. | Health Services |
Bedrijven in privébezit | 5 |
---|---|
Hill-Rom Holdings, Inc.
Hill-Rom Holdings, Inc. Hospital/Nursing ManagementHealth Services Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL. | Health Services |
Global Pharmaceutical Group | |
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Q Squared Solutions Holdings Ltd.
Q Squared Solutions Holdings Ltd. Medical/Nursing ServicesHealth Services Part of IQVIA Holdings, Inc., Q Squared Solutions Holdings Ltd. is a British company that provides health services. The private company is based in Reading, UK. | Health Services |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |